MASTER DAPT



Overview
Investigator-initiated
global randomized study
global randomized study
4,579 patients,
140 hospital worldwide, 30 countries
140 hospital worldwide, 30 countries
All-comers trial in
HBR patients after PCI
HBR patients after PCI
Abbreviated vs prolonged
DAPT in patients treated with
the Utltimaster™and Ultimaster™ Tansei™ DES
DAPT in patients
treated with the
Ultimaster™ and
Ultimaster™Tansei™
DES
treated with the
Ultimaster™ and
Ultimaster™Tansei™
DES
Study Design


Primary Endpoint
・Net adverse clinical events (NACE) defined as a composite of death from any cause, myocardial infarction, stroke or major bleeding.
・Major adverse cardiac and cerebrovascular events (MACCE), defined as a composite of death from any cause, myocardial infarction, stroke or major bleeding.
・Major or clinically relevant non-major bleeding (MCB), defined as BARC 2, 3 or 5 bleeding.
Result
NACE
Difference in cumulative incidence,
0.23 percentage points (95% CI, 1.80 to 1.33)
P<0.001 for noninferiority
0.23 percentage points (95% CI, 1.80 to 1.33)
P<0.001 for noninferiority

MACCE
Difference in cumulative incidence,
0.11 percentage points (95% CI, 1.29 to 1.51)
P=0.001 for noninferiority

Major or clinically relevant non-major bleeding
Difference in cumulative incidence,
-2.82 percentage points (95% CI, 4.40 to 1.24)
P<0.001 for superiority
-2.82 percentage points (95% CI, 4.40 to 1.24)
P<0.001 for superiority

Movie
ESC TV @ #ESCCongress 2021
Speaker - Dr. Marco
Interview about MASTR DAPT Trial
MASTER DAPT study is sponsored by the European Cardiovascular Research Institute (ECRI, Rotterdam, The Netherlands) and supported with a restricted research grant by Terumo Europe.